CTXR vs EXAS · rev $7.1M vs rev $2.76B
Citius Pharmaceuticals Inc (CTXR) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Citius Pharmaceuticals Inc (CTXR) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported CTXR revenue for 2026-06-30 was $7.1M. Net income was -$49.4M. Revenue was up 26.6% from 2026-03-31 to 2026-06-30. CTXR currently screens at market cap $13.4M.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
CTXR currently screens at market cap $13.4M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the CTXR and EXAS stock pages for the full models.
Not investment advice.